Literature DB >> 14473065

A review of oral hypoglycemic agents.

W S METZLER.   

Abstract

Keywords:  ANTIDIABETICS

Mesh:

Substances:

Year:  1962        PMID: 14473065      PMCID: PMC1849513     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  9 in total

1.  Ultrastructural changes in islets of the rat produced by tolbutamide.

Authors:  J R WILLIAMSON; P E LACY; J W GRISHAM
Journal:  Diabetes       Date:  1961 Nov-Dec       Impact factor: 9.461

2.  Experiences with phenformin. A two-year study.

Authors:  R S WALKER; R HANNAH
Journal:  Diabetes       Date:  1961 Jul-Aug       Impact factor: 9.461

3.  Clinical use of the biguanides and their role in stabilizing juvenile-type diabetes.

Authors:  L P KRALL; P WHITE; R F BRADLEY
Journal:  Diabetes       Date:  1958 Nov-Dec       Impact factor: 9.461

4.  Metabolic and endocrine studies with phenethyldiguanide (DBI).

Authors:  T G SKILLMAN; F A KRUGER; G J HAMWI
Journal:  Diabetes       Date:  1959 Jul-Aug       Impact factor: 9.461

5.  Clinical experience with chlorpropamide in the treatment of diabetes.

Authors:  G G DUNCAN
Journal:  Diabetes       Date:  1959 Sep-Oct       Impact factor: 9.461

6.  Tolbutamide-induced improvement in carbohydrate tolerance of young people with mild diabetes mellitus.

Authors:  S S FAJANS; J W CONN
Journal:  Diabetes       Date:  1960 Mar-Apr       Impact factor: 9.461

7.  The correlation between oral dosage, blood levels, and clinical and metabolic activity of chlorpropamide in the treatment of diabetes mellitus.

Authors:  S B BEASER
Journal:  Ann N Y Acad Sci       Date:  1959-03-30       Impact factor: 5.691

8.  Severe hypoglycemia caused by chlorpropamide.

Authors:  R D LINDEMAN
Journal:  Diabetes       Date:  1960 Mar-Apr       Impact factor: 9.461

9.  The effect of BZ-55 (carbutamide) on pancreatic diabetes following pancreatectomy.

Authors:  M A OGRYZLO; J HARRISON
Journal:  Can Med Assoc J       Date:  1956-06-15       Impact factor: 8.262

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.